Evidence map›Paper›PMID 18928523›Full record

ArticleRetrovirology2008

SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys.

Michael Humbert, Robert A Rasmussen, Ruijiang Song, Helena Ong, Prachi Sharma, Agnès L Chenine, Victor G Kramer, Nagadenahalli B Siddappa, Weidong Xu, James G Else and 4 more

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 71 citations in OpenAlex.

  1. CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Michael HumbertDana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. michael_humbert@dfci.harvard.edu
Robert A Rasmussen
Ruijiang Song
Helena Ong
Prachi Sharma
Agnès L Chenine
Victor G Kramer
Nagadenahalli B Siddappa
Weidong Xu
James G Else
Francis J Novembre
Elizabeth Strobert
Shawn P O'Neil
Ruth M Ruprecht
Dana-Farber Cancer Institute · USEmory University · USLemuel Shattuck Hospital · USHarvard University · US

Funding

YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI JOHNS, MICHAEL M · 1985 to 2011
$114.0M
Virology and ImmunologyP01AI048240 · NIAID · UNIVERSITY OF WASHINGTON · PI RUPRECHT, RUTH MARGRIT · 2000 to 2020
$46.7M
NCRR NIH HHS P51 RR000165NCRR NIH HHS RR-00165NIAID NIH HHS P01 AI048240
6 · The paper itself

Abstract

backgroundInfection of nonhuman primates with simian immunodeficiency virus (SIV) or chimeric simian-human immunodeficiency virus (SHIV) strains is widely used to study lentiviral pathogenesis, antiviral immunity and the efficacy of AIDS vaccine candidates. SHIV challenges allow assessment of anti-HIV-1 envelope responses in primates. As such, SHIVs should mimic natural HIV-1 infection in humans and, to address the pandemic, encode HIV-1 Env components representing major viral subtypes worldwide.

resultsWe have developed a panel of clade C R5-tropic SHIVs based upon env of a Zambian pediatric isolate of HIV-1 clade C, the world's most prevalent HIV-1 subtype. The parental infectious proviral clone, SHIV-1157i, was rapidly passaged through five rhesus monkeys. After AIDS developed in the first animal at week 123 post-inoculation, infected blood was infused into a sixth monkey. Virus reisolated at this late stage was still exclusively R5 tropic and mucosally transmissible. Here we describe the long-term follow-up of this initial cohort of six monkeys. Two have remained non-progressors, whereas the other four gradually progressed to AIDS within 123-270 weeks post-exposure. Two progressors succumbed to opportunistic infections, including a case of SV40 encephalitis.

conclusionThese data document the disease progression induced by the first mucosally transmissible, pathogenic R5 non-clade B SHIV and suggest that SHIV-1157i-derived viruses, including the late-stage, highly replication-competent SHIV-1157ipd3N4 previously described (Song et al., 2006), display biological characteristics that mirror those of HIV-1 clade C and support their expanded use for AIDS vaccine studies in nonhuman primates.

Indexed as

Acquired Immunodeficiency SyndromeAmino Acid SequenceAnimalsCell LineHIV-1HumansMacaca mulattaMolecular Sequence DataSequence AlignmentSerial PassageSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral Envelope ProteinsViral LoadVirus ReplicationViral Envelope Proteins

Identifiers

PMID18928523
PMCPMC2576354
OpenAlexW2071287349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.